Torralva Medical Therapeutics

Torralva Medical Therapeutics is a private U.S. drug development company focused on next-generation therapeutics for fentanyl and other synthetic opioid overdose. The company is developing intranasal and intramuscular combination formulations intended to reverse overdose effects that may be resistant to naloxone, including vocal cord closure, chest wall rigidity, and respiratory depression. Its approach is based on a proprietary preclinical model of fentanyl toxicity and a patent portfolio covering compositions and methods for opioid and stimulant overdose prevention and reversal. The company also describes longer-term ambitions in medication-assisted treatment for opioid use disorder and chemical weapon countermeasures. Operations appear to remain at the preclinical stage, supported by NIH/NIDA SBIR and STTR funding.